KBC Group NV Acquires 1,120 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

KBC Group NV lifted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 65.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,839 shares of the life sciences company’s stock after purchasing an additional 1,120 shares during the period. KBC Group NV’s holdings in Integra LifeSciences were worth $52,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. boosted its position in shares of Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares in the last quarter. CWM LLC boosted its holdings in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after buying an additional 425 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in shares of Integra LifeSciences during the third quarter worth $73,000. Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the second quarter worth about $114,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Up 2.5 %

Shares of NASDAQ IART opened at $23.58 on Friday. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $45.42. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market cap of $1.82 billion, a PE ratio of -262.00, a P/E/G ratio of 0.78 and a beta of 1.08. The company’s fifty day simple moving average is $20.08 and its 200 day simple moving average is $24.03.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.76 EPS. As a group, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. JMP Securities decreased their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Bank of America dropped their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $24.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.